One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company

生物制药研发人员面临的最大挑战之一是药效不稳定和副作用危险。生物科技公司

kyron.bio

凯隆生物

today announced a €5.5 million funding round to solve these issues using precise control of sugar molecules found on the surface of a drug – also known as glycans.

今天宣布了一轮 550 万欧元的融资，用于通过精确控制药物表面的糖分子（也称为聚糖）来解决这些问题。

The seed funding round was led by HCVC, with the participation of Verve Ventures, Entrepreneur First, Saras Capital, and numerous reputable angel investors. The funds will accelerate the development of kyron.bio’s proprietary glycan-engineering platform, expand the kyron.bio team and fuel preclinical studies.

种子轮融资由HCVC领投，Verve Ventures、Entrepreneur First、Saras Capital以及众多知名天使投资人参与。这笔资金将加速kyron.bio专有的聚糖工程平台的开发，扩充kyron.bio团队，并推动临床前研究。

Additionally, the funding coincides with the launch of the company’s EIC Transition project, backed by the European Innovation Council..

此外，这笔资金与公司由欧洲创新委员会支持的EIC过渡项目启动相吻合。

The company’s vision is to open a new design space for next-generation therapeutics using glycans and to partner with pharmaceutical companies to develop safer, more potent treatments for patients. kyron.bio focuses its technology specifically on antibody therapeutics, a majorly important class of drugs that harness the precision of the immune system to treat a wide range of diseases, including cancer and autoimmune diseases..

公司愿景是利用聚糖为下一代疗法开辟新的设计空间，并与制药公司合作，为患者开发更安全、更有效的治疗方法。kyron.bio 专注于抗体疗法技术，这是一类极为重要的药物，能够利用免疫系统的精确性来治疗包括癌症和自身免疫疾病在内的多种疾病。

The problem with current antibody therapeutics: The patient’s body attacks the therapy

当前抗体疗法的问题：患者的身体会攻击这种疗法

One of the major problems with antibody therapeutics is the patient’s immune system recognizing the treatment as foreign and attacking it. This immune response can be harmful and render the therapeutic ineffective. As drug design becomes more complex and therefore more foreign to the human immune system, this issue is an increasing burden to biopharma companies.

抗体疗法的主要问题之一是患者的免疫系统会将治疗药物识别为外来物质并对其进行攻击。这种免疫反应可能有害，并使治疗失效。随着药物设计变得越来越复杂，因而与人类免疫系统越发“格格不入”，这一问题正成为生物制药公司日益沉重的负担。

This unwanted immune attack is problematic for patients, particularly those with chronic diseases that are treated over a long period of time. It also prevents many novel therapies from making it through the critical Phase I stage of clinical trials, where drug safety is assessed.

这种不想要的免疫攻击对患者来说是个问题，特别是那些需要长期治疗的慢性病患者。它还阻止了许多新疗法通过临床试验的关键第一阶段，即药物安全性评估阶段。

kyron.bio’s solution: Precision control over glycans to prevent unwanted immune attack

kyron.bio的解决方案：精确控制聚糖以防止不必要的免疫攻击

kyron.bio has pioneered a platform to fully control the process of N-glycosylation, the cellular mechanism that adds glycans to the surface of therapeutics. In standard biomanufacturing, this process is highly inconsistent, producing a mix of glycan structures that can trigger immune responses or reduce therapeutic efficacy.

kyron.bio 开创了一个平台，能够完全控制 N-糖基化的进程，这是在治疗药物表面添加聚糖的细胞机制。在标准生物制造中，这一过程高度不一致，会产生可能引发免疫反应或降低治疗效果的多种聚糖结构。

kyron.bio’s breakthrough enables, for the first time, the precise use of specific glycans to prevent unwanted immune attack. This platform is offered as a scalable, plug-and-play solution compatible with standard biopharma manufacturing techniques..

kyron.bio 的突破性技术首次实现了使用特定聚糖来防止不必要的免疫攻击。该平台作为一种可扩展的、即插即用的解决方案提供，兼容标准的生物制药制造技术。

This breakthrough consists of two key elements:

这一突破包括两个关键要素：

Novel engineered cell lines: Genetic manipulation of the cells used as production factories (known as Chinese Hamster Ovary cells) to produce antibodies to enable, for the first time, complete control over the glycosylation process.

新型工程细胞系：对用作生产工厂的细胞（称为中国仓鼠卵巢细胞）进行基因操控以生产抗体，从而首次实现对糖基化过程的完全控制。

Proprietary glycan-engineering toolbox: Engineering of the antibody therapeutic itself to prevent unwanted immune attack and enhance performance, while generating strong new intellectual property (IP).

专有的糖工程工具箱：对抗体药物本身进行工程改造，以防止不必要的免疫攻击并增强性能，同时生成强大的新知识产权 (IP)。

Together, these technologies allow kyron.bio’s platform to achieve over 97% consistency in glycan structures – an unprecedented level compared to standard bioproduction methods.

这些技术共同使 kyron.bio 的平台能够实现超过 97% 的聚糖结构一致性——相比于标准的生物生产方法，这一水平前所未有。

This level of glycan control unlocks transformative opportunities in antibody engineering, enabling biologic therapies that can resist degradation, evade immune detection, and target diseases with unprecedented specificity.

这种聚糖控制水平在抗体工程中开启了变革性的机会，使得生物疗法能够抵抗降解、逃避免疫检测，并以前所未有的特异性靶向疾病。

The opportunity to partner with kyron.bio on drug design is especially pertinent to pharmaceutical companies working on next-generation monoclonal antibodies. These therapeutics often involve complex designs and multiple targets, which carry a higher risk of immune attack.

与Kyron.bio合作进行药物设计的机会对于从事下一代单克隆抗体研究的制药公司尤为重要。这些疗法通常涉及复杂的设计和多个靶点，因此面临更高的免疫攻击风险。

In chronic conditions, such as autoimmune diseases, kyron.bio’s technology unlocks the possibility for more patients to receive treatment lifelong, without developing resistance to the therapy, which is sadly the case for many patients today. In oncology, this technology massively increases the chance of drugs passing the critical Phase I stage of development, where drug safety is evaluated..

在慢性病状况下，如自身免疫性疾病，kyron.bio的技术为更多患者实现终身治疗带来了可能性，且不会对疗法产生抗性，而如今许多患者却面临着抗性问题。在肿瘤学领域，该技术大大增加了药物通过关键的I期开发阶段的机会，这一阶段主要评估药物的安全性。

Challenges like increasing therapeutic complexity and long-term treatments have made immune attack a growing obstacle. kyron.bio’s technology is designed to overcome these issues, paving the way for therapies that can reach more patients and perform better over time. Ultimately, this technology aims to unlock new treatment avenues for patients..

像治疗复杂性增加和长期治疗等挑战，使得免疫攻击成为一个日益严重的障碍。kyron.bio 的技术旨在克服这些问题，为能够惠及更多患者且随着时间的推移表现更佳的疗法铺平道路。最终，该技术旨在为患者解锁新的治疗途径。

Alexis Houssou, Founder & Managing Partner at HCVC

阿莱克西斯·胡苏，HCVC创始人兼管理合伙人

, said: “kyron.bio’s technology bridges a massive gap in therapeutics design. Their breakthrough in glycan control could shift the paradigm for antibody therapies, and we’re proud to support their vision.”

表示：“kyron.bio 的技术弥补了治疗设计中的巨大空白。他们在聚糖控制方面的突破可能会改变抗体疗法的范式，我们很自豪能够支持他们的愿景。”

Dr. Emilia McLaughlin, CEO & Founder of kyron.bio

艾米莉亚·麦克劳克林博士，kyron.bio首席执行官兼创始人

, said: “To date, glycans have been massively under-exploited, limiting their potential in drug design. By achieving comprehensive control over glycosylation in a fully scalable manner, we have unlocked the possibility to use precision glycosylation in drug design. This transforms glycans into a design tool for the first time, opening up new treatment avenues for patients.

，说道：“迄今为止，聚糖一直被大规模地忽视，限制了它们在药物设计中的潜力。通过以完全可扩展的方式全面控制糖基化，我们已经开启了在药物设计中使用精准糖基化的可能性。这首次将聚糖转化为一种设计工具，为患者开辟了新的治疗途径。

Securing this fundraising round brings us closer to our goal of delivering precision glycan-engineered therapeutics to patients.”.

“此次融资使我们更接近于向患者提供精准的糖工程疗法的目标。”

Dr. McLaughlin’s experience studying rare single-cell organisms during her PhD at Institut Pasteur Paris has largely informed kyron.bio’s approach to drug development. The startup, under her leadership, has developed the first-ever scalable, patent-protected method to unlock this molecular design problem..

麦克劳克林博士在巴黎巴斯德研究所攻读博士学位期间研究罕见单细胞生物的经验，很大程度上影响了 kyron.bio 的药物开发方法。在这位博士的领导下，这家初创公司已经开发出首个可扩展的、受专利保护的方法，以解决这一分子设计难题。